Vertex: FDA Approves Expanded Use of Orkambi for Kids With CF

Vertex Pharmaceuticals said the US FDA approved expanded use of Orkambi to include some children with cystic fibrosis from ages 2 years to 12 years.

• Approval covers those who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
• Therapy was previously approved by the FDA for use in people with CF ages 2 years and older with two copies of the F508del mutation

NOTE

• Vertex Pharmaceuticals Inc. fell 1.6% to $285.44 as of 1:17 p.m. New York time
  • The average 12-month price target of $310.80 is 8.9% above the current price
  • 20 buys, 9 holds, ...